

Heart Failure

Bibliography of One Hundred Key Papers

selected by **Luigi Tavazzi, MD, FESC, FASC; Eloisa Arbustini, MD, FESC**
Department of Cardiology - Policlinico S. Matteo - Institute of Care and Research (IRCCS) - Pavia - ITALY

-
- ACC/AHA 2002 Guidelines update for the management of patients with chronic stable angina.** *A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.*
www.acc.org; www.americanheart.org.
Accessed 15 December 2004.
-
- Arbustini E, Diegoli M, Fasani R, et al.** *Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy.*
Am J Pathol. 1998;153:1501-1510.
-
- Arbustini E, Diegoli M, Morbini P, et al.** *Prevalence and characteristics of dystrophin defects in adult male patients with dilated cardiomyopathy.*
J Am Coll Cardiol. 2000;35:1760-1768.
-
- Arbustini E, Gavazzi A, Merlini G.** *Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know.*
Ital Heart J. 2002;3:590-597.
-
- Arbustini E, Morbini P, Grasso M, et al.** *Restrictive cardiomyopathy, atrioventricular block, and mild to subclinical myopathy in patients with desmin-immunoreactive material deposits.*
J Am Coll Cardiol. 1998;31:645-653.
-
- Arbustini E, Morbini P, Pilotto A, et al.** *Familial dilated cardiomyopathy: from clinical presentation to molecular genetics.*
Eur Heart J. 2000;21:1825-1832.
-
- Arbustini E, Morbini P, Pilotto A, et al.** *Genetics of idiopathic dilated cardiomyopathy.*
Herz. 2000;25:156-160.
-
- Ariza A, Coll J, Fernandez-Figueras M, et al.** *Desmin myopathy: a multisystem disorder involving skeletal, cardiac and smooth muscle.*
Hum Pathol. 1995;26:1032-1037.
-
- Armstrong PW, Ezekowitz JA, McAlister FA.** *Anaemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure.*
Circulation. 2003;107:223-225.
-
- Baig KM, Goldman JH, Caforio ALP, et al.** *Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease.*
J Am Coll Cardiol. 1998;31:195-201.
-

Bibliography of One Hundred Key Papers

- Bigger TJ, for the Coronary Artery Bypass Graft Patch Trial Investigators.** *Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. CAPRICORN trial.*
N Engl J Med. 1997;337:1569-1575.
-
- Blaxal BC, Tschannen-Moran BM, Milano CA.** *Differential gene expression and genomic patient stratification following left ventricular assist device support.*
J Am Coll Cardiol. 2003;41:1096-1106.
-
- Bouvy ML, Heerdink ER, Leufkens HGM, et al.** *Predicting mortality in patients with heart failure: pragmatic approach.*
Heart. 2003;89:1255-1264.
-
- Brancaccio M, Fratta L, Notte A, et al.** *Melusin, a muscle-specific integrin beta₁-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload.*
Nat Med. 2003;9:68-75.
-
- Breithardt OA, Claus P, Sutherland GR.** *Do we understand who benefits from resynchronisation therapy?*
Eur Heart J. 2004 ;25:535-536.
-
- Brenner BM, Cooper M, De Zeeuw D, et al.** *Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. (RENAAL trial.)*
N Engl J Med. 2001;345: 861-869.
-
- Bristow MR, Saxon LA, Boehmer J, et al.** *Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.*
N Engl J Med. 2004;350:2140-2150.
-
- Cesari M, Penninx B, Newman A, et al.** *Inflammatory markers and onset of cardiovascular events. Results from the health ABC study.*
Circulation. 2003;108:2317-2322.
-
- Cleland JGF, Thygesen K, Uretsky BF, et al.** *Cardiovascular critical event pathways for the progression of heart failure.*
Eur Heart J. 2001;22:1601-1612.
-
- Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators.** *A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure.*
N Engl J Med. 2001;345:1667-1675.
-
- Corrà U, Mezzani A, Bosimini E, et al.** *Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity.*
Am Heart J. 2002;143:418-426.
-
- Cowburn PJ, Cleland JGF, Coats AJ, et al.** *Risk stratification in chronic heart failure.*
Eur Heart J. 1998;19:696-710.
-
- Crispell KA, Hanson EL, Coates K, et al.** *Periodic rescreening is indicated for family members at risk of developing familial dilated cardiomyopathy.*
J Am Coll Cardiol. 2002;39:1503-1507.
-
- Dahlöf B, Devereux RB, Kjeldsen SE, et al.** *Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.*
Lancet. 1998;27:808-813.
-



-
- Deswal A, Misra A, Bozkurt B.** *The role of anti-cytokine therapy in the failing heart.*
Heart Fail Rev. 2001;61:143-151.
-
- Dries DL, Exner DV, Domanski MJ, et al.** *The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.*
J Am Coll Cardiol. 2000;102:681-689.
-
- Duncan A, Wait D, Gibson D, et al.** *Left ventricular remodelling and haemodynamic effects of multisite biventricular pacing in patients with left ventricular systolic dysfunction and activation disturbances in sinus rhythm: sub-study of the MUSTIC trial.*
Eur Heart J. 2003;24:430-431.
-
- Eichhorn EJ.** *Prognosis determination in heart failure.*
Am Heart J. 2001;110(suppl 7A):14S-35S.
-
- Elliott P, McKenna WJ.** *Hypertrophic cardiomyopathy.*
Lancet. 2004;363:1881-1891.
-
- Felker M, Benza RL, Chandler B, et al, for the OPTIME Investigators.** *Heart failure etiology and response to milrinone in decompensated heart failure.*
J Am Coll Cardiol. 2003;41:997-1003.
-
- Felker MG, Shaw LK, O'Connor CM.** *A standardized definition of ischemic cardiomyopathy for use in clinical research.*
J Am Coll Cardiol. 2002;39:210-218.
-
- Follath F, Cleland JGF, Just H, et al.** *Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.*
Lancet. 2002;360:196-202.
-
- Fox KM and the EUROpean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease Investigators.** *Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA trial).*
Lancet. 2003;362:782-788.
-
- Franz WM, Muller OJ, Katus HA.** *Cardiomyopathies: from genetics to the prospect of treatment.*
Lancet. 2001;358:1627-1637.
-
- Gavazzi A, Repetto A, Scelsi L, et al.** *Evidence-based diagnosis of familial non X-linked dilated cardiomyopathy. Prevalence, inheritance and characteristics.*
Eur Heart J. 2001;22:73-81.
-
- Ghio S, Gavazzi A, Campana C, et al.** *Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure.*
J Am Coll Cardiol. 2001;37:183-188.
-
- GISSI-Prevenzione Investigators.** *Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.*
Lancet. 1999;354:447-455.
-
- Goldfarb LG, Vicart P, Goebel HH, et al.** *Desmin myopathy.*
Brain. 2004;127:723-734.
-

Bibliography of One Hundred Key Papers

- Grigioni F, Barbieri A, Magnani G, et al.** *Serial versus isolated assessment of clinical and instrumental parameters in heart failure: prognostic and therapeutic implications.* **Am Heart J.** 2003;146:298-303.
-
- Gustafsson F, Torp-Pedersen C, Brendorp B, et al.** *Long-term survival in patients hospitalised with congestive heart failure: relation to preserved and reduced left ventricular systolic function.* **Eur Heart J.** 2004;24:863-870.
-
- Horwich TB, Fonarow GC, Hamilton MA, et al.** *Anaemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.* **J Am Coll Cardiol.** 2002;39:1780-1786.
-
- Huikuri V, Makikallio TH, Raatikainen P, et al.** *Prediction of sudden cardiac death. Appraisal of the studies and methods assessing the risk of sudden arrhythmic death.* **Circulation.** 2003;108:110-115.
-
- Jong P, Yusuf S, Rousseau MF.** *Effect of enalapril on 12-year survival and life expectancy inpatients with left ventricular systolic dysfunction: a follow-up study.* **Lancet.** 2003;361:1843-1848.
-
- Kadish A, Dyer A, Daubert J, et al.** *Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.* **N Engl J Med.** 2004;350:2151-2158.
-
- Kearney MT, Fox KA, Lee AJ, et al.** *Predicting death due to progressive heart failure in patients with mild to moderate chronic heart failure.* **J Am Coll Cardiol.** 2002;40:1801-1808.
-
- Keller DI, Carrier L, Schwartz K.** *Genetics of familial cardiomyopathies and arrhythmias.* **Swiss Med Wkly.** 2002;132:401-407.
-
- Koukkunen H, Penttila K, Kempaninen A, et al.** *C-reactive protein, fibrinogen, interleukin-6 and tumor necrosis factor- α in the prognostic classification of unstable angina pectoris.* **Ann Intern Med.** 2001;33:37-47.
-
- Krumholtz HM, Amatruda J, Smith GL, et al.** *Randomized trial of an education and support intervention to prevent readmission of patients with heart failure.* **J Am Coll Cardiol.** 2003;39:83-89.
-
- La Rovere MT, Pinna GD, Maestri R, et al.** *Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients.* **Circulation.** 2003;107:565-570.
-
- Levy D, Kenchaina S, Larson M, et al.** *Long-term trends in the incidence of and survival with heart failure.* **N Engl J Med.** 2002;18:1397-1402.
-
- Maass AH, Leinwand LA.** *Mechanisms of the pathogenesis of troponin T-based familial hypertrophic cardiomyopathy.* **Trends Cardiovasc Med.** 2003;13:232-237.
-
- Maggioni AP, Sinagra G, Opasich C, et al.** *Beta-blockers in patients with congestive heart failure: guided use in clinical practice investigators. Treatment of chronic heart failure with beta-adrenergic blockade beyond controlled clinical trials: the BRING-UP experience.* **Heart.** 2003;89:299-305.
-



-
- Mann DL, MC Murray JV, Packer M, et al.** *Targeted anticytokine therapy in patients with chronic heart failure: results of the randomised etanercept worldwide evaluation (RENEWAL).*
Circulation. 2004;109:1594-1602.
-
- Maron BJ.** *Hypertrophic cardiomyopathy. A systematic review.*
JAMA. 2002;287:1308-1320.
-
- Masoudi FA, Krumholz HM.** *Polypharmacy and comorbidity in heart failure.*
BMJ. 2003;327:513-514.
-
- Mestroni L, Maisch B, McKenna WJ, et al.** *Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy.*
Eur Heart J. 1999;20:93-102.
-
- Mezzani A, Corrà U, Bosimini E, et al.** *Contribution of peak respiratory exchange ratio to peak VO₂ prognostic reliability in patients with chronic heart failure and severely reduced exercise capacity.*
Am Heart J. 2003;145:1102-1107.
-
- Moiseyev VS, Poder P, Andrejevs N, et al.** *Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomised, placebo-controlled, double-blind study (RUSSLAN).*
Eur Heart J. 2002;23:1422-1432.
-
- Moss AJ, Zareba W, Hall WJ, et al.** *Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.*
N Engl J Med. 2002;346:877-883.
-
- Mozaffarian D, Nye R, Levy WC.** *Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE).*
J Am Coll Cardiol. 2003;41:1933-1939.
-
- Nohria A, Tsang SW, Fang JC, et al.** *Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure.*
J Am Coll Cardiol. 2003;41:1797-1804.
-
- Oosterga M, Voors AA, Buikema H, et al.** *Angiotensin II formation in human vasculature after chronic ACE-inhibition: a prospective, randomised, placebo-controlled study. QUO VADIS Investigators.*
Cardiovasc Drugs Ther. 2000;14:55-60.
-
- Opasich C, Pinna GD, Bobbio M, et al.** *Peak oxygen consumption in chronic heart failure: toward efficient use in the individual patient.*
J Am Coll Cardiol. 1998;31:766-775.
-
- Opasich C, Pinna GD, Mazza A, et al.** *Reproducibility of the six-minute walking test in patients with chronic congestive heart failure: practical implications.*
Am J Cardiol. 1998;81:1497-1500.
-
- Packer M.** *The neurohormonal hypothesis. A theory to explain the mechanism of disease progression in heart failure.*
J Am Coll Cardiol. 1992;20:248-254.
-

Bibliography of One Hundred Key Papers

- Pasotti M, Repetto A, Pisani A, et al.** Diseases associated with lamin A/C gene defects: what the clinical cardiologist ought to know. **Ital Heart J Suppl.** 2004;5:98-111.
-
- Pepine CJ, Rouleau JL, Annis K, et al.** Effects of angiotensin-converting enzyme inhibition on transient ischemia: the quinapril anti-ischemia and symptoms of angina reduction (QUASAR trial). **J Am Coll Cardiol.** 2003;42:2049-2059.
-
- Pfeffer MA, Mc Murray JV, Velasquez EJ, et al.** Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. VALIANT trial. **N Engl J Med.** 2003;349:1893-1906.
-
- Ponikowski P, Francis Darrel, Piepoli M, et al.** Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance. **Circulation.** 2002;103:967-976.
-
- Salukhe T, Dimopoulos K, Sutton R, et al.** Life-years gained from defibrillator implantation. Markedly non-linear increase during 3 years of follow-up and its implications. **Circulation.** 2004;109:1848-1853.
-
- Schaufelberger M, Swedberg K, Köster M, et al.** Decreasing one-year mortality and hospitalization rates for heart failure in Sweden: data from the Swedish Hospital Discharge Registry 1988 to 2000. **Eur Heart J.** 2004;25:300-307.
-
- Silverberg DS, Wexler D, Sheps D, et al.** The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. **J Am Coll Cardiol.** 2001;37:1775-1780.
-
- Smith G, Masoundi FS, Vaccarino V, et al.** Outcomes in heart failure patients with preserved ejection fraction. **J Am Coll Cardiol.** 2003;41:1510-1518.
-
- Staessen JA, Fagard R, Thijs L, et al.** Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. (SYST-EUR trial). **Lancet.** 1997;350:757-764.
-
- Stevenson LW.** Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: Inotropic infusions during hospitalization. **Circulation.** 2003;108:367-372.
-
- Stewart S, Blue L, Walker A, et al.** An economic analysis of specialist heart failure nurse management in the UK: can we afford not to implement it? **Eur Heart J.** 2002;23:1369-1378.
-
- Stewart S, Marley JE, Horowitz JD.** Effects of a multidisciplinary, home-based intervention on unplanned readmission and survival among patients with chronic congestive heart failure: a randomised controlled study. **Lancet.** 1999;354:1077-1083.
-
- Strömberg A, Martensson J, Fridlund B, et al.** Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure. **Eur Heart J.** 2003;24:1014-1023.
-



-
- Swedberg K, Kjeksus J, Snapinn S.** *Long-term survival in severe heart failure in patients treated with enalapril: ten years follow-up of CONSENSUS I.*
Eur Heart J. 1999;20:136-139.
-
- Tavazzi L, Tognoni G, Franzosi MG, et al.** *Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure.*
Eur J Heart Fail. 2004;6:635-641.
-
- Tesson F, Sylvius N, Pilotto A, et al.** *Epidemiology of desmin and cardiac actin gene mutations in a European population of dilated cardiomyopathy.*
Eur Heart J. 2000;21:1872-1876.
-
- The ALLHAT Collaborative Research Group.** *The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial).*
JAMA. 2002;288:2981-2997.
-
- The AVID Investigators.** *The antiarrhythmics versus implantable defibrillators.*
N Engl J Med. 1997;337:1576-1583.
-
- The Heart Outcomes Prevention Evaluation Study Investigators.** *Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. (HOPE trial).*
N Engl J Med. 2000;342:145-153.
-
- Vasan RS, Sullivan LM, Roubenoff R, et al.** *Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham heart study.*
Circulation. 2003;107:1486-1491.
-
- Verrier RL, Tolath AV, Josephson ME.** *T-wave alternans for arrhythmia risk stratification in patients with idiopathic dilated cardiomyopathy.*
J Am Coll Cardiol. 2003;14:2225-2227.
-
- Von Harsdorf R, Poole-Wilson P, Dietz R.** *Regenerative capacity of the myocardium: implications for treatment of heart failure.*
Lancet. 2004;363:1306-1313.
-
- Weingarten SR, Hennin JM, Badamgarav E, et al.** *Interventions used in disease management programmes for patients with chronic illness— which ones work? Meta-analysis of published reports.*
BMJ. 2002;325:1-8.
-
- Whang W, Mittleman M, Rich DQ, et al.** *Heart failure and the risks of shocks in patients with implantable cardioverter defibrillators. Results from the triggers of ventricular arrhythmias (TOVA) study.*
Circulation. 2004;109:1368-1391.
-
- Working Group on Cardiac Rehabilitation and Exercise Physiology and Working Group on Heart Failure of the European Society of Cardiology.** *Recommendations for exercise testing in chronic heart failure patients.*
Eur Heart J. 2001;22:37-45.
-
- Wright SP, Walsh H, Ingley KM, et al.** *Uptake of self-management strategies in a heart failure management programme.*
Eur J Heart Fail. 2003;5:371-380.
-

Bibliography of One Hundred Key Papers

Young JB, Abraham WT, Smith AL, et al.

Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial.

JAMA. 2003;289:2685-2694.

Yusuf S, Pferrer M, Swedberg M, et al.

Effect of candesartan in patients with chronic heart failure and preserved left-ventricular ejection: the CHARM-Preserved trial.

Lancet. 2003;362:777-781.

Zile MR.

Heart failure with preserved ejection fraction: is this diastolic heart failure?

J Am Coll Cardiol. 2003;41:1519-1522.
